Top-tier investor syndicate led by FoundersX Ventures, with participation from all existing investors and new investors Alzheimer’s Drug Discovery Foundation (ADDF), Starbloom Capital, IAG Capital and ...

CAMBRIDGE, Mass., November 18, 2025--(BUSINESS WIRE)--Cognito Therapeutics, a clinical-stage medical device company pioneering non-invasive neuroprotection against neurodegenerative diseases, ...

- Long-term, daily proprietary gamma sensory stimulation was shown to be safe and well tolerated; treatment integrated well into subjects' daily lives. - Pivotal trials will launch this year to ...

Cognito Therapeutics has presented new data demonstrating its Spectris neuromodulation device’s potential to slow cognitive decline and preserve white matter in patients with mild to moderate ...

CAMBRIDGE, Mass., December 03, 2025--(BUSINESS WIRE)--Cognito Therapeutics, a clinical-stage medical device company pioneering non-invasive neuroprotective therapies in neurodegenerative diseases, ...

As it plows ahead in its efforts to secure an FDA greenlight for its light- and sound-based neuromodulation device to treat Alzheimer’s disease, Cognito Therapeutics is taking an even closer look at ...

Forbes contributors publish independent expert analyses and insights. I’m an analyst covering neurotech's impact on business and society. Cognito Therapeutics and West Virginia University’s ...

Riding high on early clinical trial results showing that its neuromodulation headset can improve memory and cognition and slow the deterioration of white matter in the brains of people with ...

Cognito Therapeutics, a neurotechnology company advancing disease-modifying therapies to treat CNS diseases, today announced the publication of a study in Alzheimer's & Dementia: Translational ...

Alzheimer's disease is a complicated and debilitating disease that has no cure. One startup is testing whether a "disco" of light and sound can slow the disease in patients. Cognito Therapeutics ...